Literature DB >> 19740978

Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Steve Bryson1, Jean-Philippe Julien, Rosemary C Hynes, Emil F Pai.   

Abstract

The quest to create a human immunodeficiency virus type 1 (HIV-1) vaccine capable of eliciting broadly neutralizing antibodies against Env has been challenging. Among other problems, one difficulty in creating a potent immunogen resides in the substantial overall sequence variability of the HIV envelope protein. The membrane-proximal region (MPER) of gp41 is a particularly conserved tryptophan-rich region spanning residues 659 to 683, which is recognized by three broadly neutralizing monoclonal antibodies (bnMAbs), 2F5, Z13, and 4E10. In this study, we first describe the variability of residues in the gp41 MPER and report on the invariant nature of 15 out of 25 amino acids comprising this region. Subsequently, we evaluate the ability of the bnMAb 2F5 to recognize 31 varying sequences of the gp41 MPER at a molecular level. In 19 cases, resulting crystal structures show the various MPER peptides bound to the 2F5 Fab'. A variety of amino acid substitutions outside the 664DKW666 core epitope are tolerated. However, changes at the 664DKW666 motif itself are restricted to those residues that preserve the aspartate's negative charge, the hydrophobic alkyl-pi stacking arrangement between the beta-turn lysine and tryptophan, and the positive charge of the former. We also characterize a possible molecular mechanism of 2F5 escape by sequence variability at position 667, which is often observed in HIV-1 clade C isolates. Based on our results, we propose a somewhat more flexible molecular model of epitope recognition by bnMAb 2F5, which could guide future attempts at designing small-molecule MPER-like vaccines capable of eliciting 2F5-like antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740978      PMCID: PMC2772703          DOI: 10.1128/JVI.01604-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

Authors:  I Muñoz-Barroso; K Salzwedel; E Hunter; R Blumenthal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.

Authors:  E Coëffier; J M Clément; V Cussac; N Khodaei-Boorane; M Jehanno; M Rojas; A Dridi; M Latour; R El Habib; F Barré-Sinoussi; M Hofnung; C Leclerc
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

3.  The pre-transmembrane region of the human immunodeficiency virus type-1 glycoprotein: a novel fusogenic sequence.

Authors:  T Suárez; S Nir; F M Goñi; A Saéz-Cirión; J L Nieva
Journal:  FEBS Lett       Date:  2000-07-14       Impact factor: 4.124

Review 4.  Viral persistence: HIV's strategies of immune system evasion.

Authors:  Welkin E Johnson; Ronald C Desrosiers
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

5.  Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion.

Authors:  T Suárez; W R Gallaher; A Agirre; F M Goñi; J L Nieva
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.

Authors:  X Liang; S Munshi; J Shendure; G Mark; M E Davies; D C Freed; D C Montefiori; J W Shiver
Journal:  Vaccine       Date:  1999-07-16       Impact factor: 3.641

7.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

8.  Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

Authors:  A Alfsen; P Iniguez; E Bouguyon; M Bomsel
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

9.  The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles.

Authors:  D J Schibli; R C Montelaro; H J Vogel
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

10.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  29 in total

1.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

2.  Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

Authors:  Anthony P West; Louise Scharf; Joshua Horwitz; Florian Klein; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

3.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

4.  Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors:  Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

5.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.

Authors:  Soraya Serrano; Aitziber Araujo; Beatriz Apellániz; Steve Bryson; Pablo Carravilla; Igor de la Arada; Nerea Huarte; Edurne Rujas; Emil F Pai; José L R Arrondo; Carmen Domene; María Angeles Jiménez; José L Nieva
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

7.  Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Authors:  Robyn L Stanfield; Jean-Philippe Julien; Robert Pejchal; Johannes S Gach; Michael B Zwick; Ian A Wilson
Journal:  J Mol Biol       Date:  2011-10-15       Impact factor: 5.469

8.  Topological analysis of the gp41 MPER on lipid bilayers relevant to the metastable HIV-1 envelope prefusion state.

Authors:  Yi Wang; Pavanjeet Kaur; Zhen-Yu J Sun; Mostafa A Elbahnasawy; Zahra Hayati; Zhi-Song Qiao; Nhat N Bui; Camila Chile; Mahmoud L Nasr; Gerhard Wagner; Jia-Huai Wang; Likai Song; Ellis L Reinherz; Mikyung Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-17       Impact factor: 11.205

Review 9.  Role of humoral immunity in host defense against HIV.

Authors:  Linda L Baum
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.